Connective tissue growth factor in serum as a new candidate test for assessment of hepatic fibrosis
Connective tissue growth factor in serum as a new candidate test for assessment of hepatic fibrosis
复制标题
DOI：
10.1373/clinchem.2006.070466
复制
发表时间：
2006-09-01
影响因子：
9.3
通讯作者：
Stanzel, Sven
中科院分区：
文献类型：
--
作者：
Gressner, Axel M.;Yagmur, Eray;Stanzel, Sven
背景资料：没有可靠的，具有成本效益的血清检测可用于评估肝纤维化，慢性炎症性肝病（CLD）最严重的并发症。在CLD患者的血清中，我们确定了结缔组织生长因子（CTGF），分泌的下游介质的有效的纤维化细胞因子转化生长因子β（TGF-β）的浓度。患者和方法：我们研究了83例CLD（17例慢性肝炎，16例组织学证实的纤维化，50例肝硬化）和74名健康人。结果：肝纤维化组和慢性病毒性肝炎组CTGF平均浓度分别为5.2倍和4.3倍，而肝硬化组CTGF平均浓度较低。CTGF对于纤维化与对照的ROC曲线下面积（AUC）为0.955（95%置信区间，0.890-0.987）。CTGF/血小板比值将肝硬化的检出限从84%提高到92%，特异性从85%提高到87.5%（CTGF的临界值为364 μ g/L，比值为2.05）。(c)2006年美国临床化学协会。
Background: No reliable, cost-effective serum test is available for assessment of liver fibrogenesis, the most serious complication of chronic inflammatory liver diseases (CLD). In sera of patients with CLD, we determined the concentration of connective tissue growth factor (CTGF), a secreted downstream mediator of the potent fibrogenic cytokine transforming growth factor beta (TGF-beta).Patients and Methods: We studied 83 patients with CLD (17 with chronic hepatitis, 16 with histologically proven fibrosis, and 50 with cirrhosis) and 74 healthy individuals. Serum CTGF was measured by use of a sandwich immunoassay.Results: The mean concentration of CTGF was highest in the fibrosis group (5.2-fold) and in the chronic viral hepatitis group (4.3-fold) but lower in those patients with fully developed cirrhosis. The area under the ROC curve (AUC) of CTGF for fibrosis vs control was 0.955 (95% confidence interval, 0.890-0.987). The CTGF/platelet ratio increased the detection limit for cirrhosis from 84% to 92% and the specificity from 85% to 87.5% (cutoff for CTGF was 364 mu g/L, ratio 2.05).Conclusion: CTGF in serum is a candidate marker of ongoing fibrogenesis in chronic liver diseases. (c) 2006 American Association for Clinical Chemistry.